THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $1,658,000 | -6.4% | 1,750,000 | 0.0% | 0.11% | -16.4% |
| Q1 2021 | $1,772,000 | +7.5% | 1,750,000 | 0.0% | 0.13% | +8.5% |
| Q4 2020 | $1,648,000 | +57.0% | 1,750,000 | +45.8% | 0.12% | +29.7% |
| Q3 2020 | $1,050,000 | -9.2% | 1,200,000 | 0.0% | 0.09% | -9.9% |
| Q2 2020 | $1,156,000 | -50.7% | 1,200,000 | -50.8% | 0.10% | -51.2% |
| Q1 2020 | $2,343,000 | -7.3% | 2,440,000 | 0.0% | 0.21% | +23.2% |
| Q4 2019 | $2,527,000 | +21.7% | 2,440,000 | +8.4% | 0.17% | +11.3% |
| Q3 2019 | $2,076,000 | -12.6% | 2,250,000 | -18.2% | 0.15% | -14.2% |
| Q2 2019 | $2,376,000 | -11.2% | 2,750,000 | -0.5% | 0.18% | -21.4% |
| Q1 2019 | $2,676,000 | -13.5% | 2,763,000 | -8.1% | 0.22% | -22.5% |
| Q4 2018 | $3,094,000 | -12.6% | 3,007,000 | 0.0% | 0.29% | +5.9% |
| Q3 2018 | $3,541,000 | +20.5% | 3,007,000 | 0.0% | 0.27% | +13.8% |
| Q2 2018 | $2,939,000 | -3.4% | 3,007,000 | 0.0% | 0.24% | -2.8% |
| Q1 2018 | $3,042,000 | -7.3% | 3,007,000 | 0.0% | 0.25% | -9.9% |
| Q4 2017 | $3,283,000 | -10.9% | 3,007,000 | 0.0% | 0.27% | -12.7% |
| Q3 2017 | $3,683,000 | -9.2% | 3,007,000 | 0.0% | 0.31% | -12.0% |
| Q2 2017 | $4,055,000 | +6.7% | 3,007,000 | 0.0% | 0.36% | +2.3% |
| Q1 2017 | $3,802,000 | +65.7% | 3,007,000 | +50.4% | 0.35% | +66.2% |
| Q4 2016 | $2,295,000 | – | 2,000,000 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|